These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38296628)

  • 1. [Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].
    Deng L; Yang Y; Huang J
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting
    Baik CS; Myall NJ; Wakelee HA
    Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
    Turshudzhyan A; Vredenburgh J
    Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
    Jiang L; Yang P; Liu Y; Li J
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V
    Metzenmacher M; Goetz M; Herold T; Stuschke M; Aigner C; Darwiche K; Eberhardt WE; Schuler M; Wiesweg M
    Clin Lung Cancer; 2021 Sep; 22(5):e668-e672. PubMed ID: 33551244
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
    Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
    Riudavets M; Cascetta P; Planchard D
    Lung Cancer; 2022 Jul; 169():102-114. PubMed ID: 35696864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
    Tsamis I; Gomatou G; Chachali SP; Trontzas IP; Patriarcheas V; Panagiotou E; Kotteas E
    Clin Transl Oncol; 2023 Jan; 25(1):10-20. PubMed ID: 35729451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Progress of BRAF Fusion in Non-small Cell Lung Cancer].
    Xiao P; Zhong D
    Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):782-788. PubMed ID: 37989341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].
    Liu X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report.
    Huang Z; Wang Y; Li B; Xu Y; Huang G; Song Y; Li J; Song L; Wang J; Wang R; Liang N; Li S
    Thorac Cancer; 2024 Aug; 15(24):1825-1828. PubMed ID: 39020500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathways and targeting avenues of BRAF in non-small cell lung cancer.
    Imyanitov EN; Mitiushkina NV; Kuligina ES; Tiurin VI; Venina AR
    Expert Opin Ther Targets; 2024 Jul; 28(7):613-622. PubMed ID: 38941191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
    Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
    J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
    Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
    Caparica R; de Castro G; Gil-Bazo I; Caglevic C; Calogero R; Giallombardo M; Santos ES; Raez LE; Rolfo C
    Crit Rev Oncol Hematol; 2016 May; 101():32-9. PubMed ID: 26960735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
    Adashek JJ; Menta AK; Reddy NK; Desai AP; Roszik J; Subbiah V
    Mol Cancer Ther; 2022 Jun; 21(6):871-878. PubMed ID: 35413124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.